Abstract: The present invention provides a system and method for diagnosing, monitoring or prognosing Multiple Sclerosis at different stages as well as affording the prediction of disease activity and response to a treatment regimen, using at least one sensor comprising carbon nanotubes or metal nanoparticles, each coated with various organic coatings in conjunction with a pattern recognition algorithm.
Type:
Grant
Filed:
August 1, 2012
Date of Patent:
February 3, 2015
Assignees:
Technion Research & Development Foundation Ltd., Mor Research Applications Ltd., Rappaport Family Institute for Research in the Medical Sciences
Abstract: Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject.
Type:
Grant
Filed:
February 28, 2010
Date of Patent:
December 16, 2014
Assignees:
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.
Type:
Grant
Filed:
June 11, 2009
Date of Patent:
December 2, 2014
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Jacob Victor, Noah Berkowitz, Andrew Levy
Abstract: The present applications describes, inter alia, a retinal light management system that allows for removal of dangerous wavelengths of light while controlling the intensity of the remaining light that is allowed to pass to a user's eyes. In one embodiment, the system involves a pair of glasses that include filters that can be modified in the presence of light to reduce total light intensity reaching a diabetic's eyes.
Type:
Grant
Filed:
July 20, 2008
Date of Patent:
September 16, 2014
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.
Type:
Application
Filed:
June 10, 2013
Publication date:
June 12, 2014
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A high affinity molecule is provided. The high affinity molecule comprises a binding domain which binds a type-A plexin receptor, wherein said binding domain inhibits proliferative signals through said type-A plexin receptor but does not interfere with binding of a neuropilin or semaphorin 6A to said type-A plexin receptor.
Type:
Application
Filed:
February 23, 2012
Publication date:
December 12, 2013
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Noa Rabinowicz, Asya Varshavsky, Ofra Kessler
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Grant
Filed:
December 7, 2011
Date of Patent:
August 20, 2013
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.
Type:
Grant
Filed:
September 11, 2006
Date of Patent:
August 20, 2013
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Grant
Filed:
December 20, 2012
Date of Patent:
July 16, 2013
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of diagnosing and determining a predisposition to prostate cancer is provided. The method comprising determining levels of MCP-1 antibodies and PSA in a sample of a subject and comparing to the level in healthy male controls, thereby diagnosing and determining a predisposition to the prostate cancer in the subject.
Type:
Grant
Filed:
May 24, 2010
Date of Patent:
July 16, 2013
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Application
Filed:
December 20, 2012
Publication date:
April 18, 2013
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventor:
Rappaport Family Institute for Research in the Me
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Grant
Filed:
August 9, 2011
Date of Patent:
April 2, 2013
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
Type:
Application
Filed:
May 5, 2011
Publication date:
February 28, 2013
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.
Type:
Grant
Filed:
June 4, 2008
Date of Patent:
September 11, 2012
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Soluble molecules are provided. Thus, for example, provided is a soluble molecule which comprises a heterologous amino acid sequence conjugated to a CCR5 amino acid sequence being capable of binding a CCR5 ligand, and wherein the molecule is devoid of an N-terminus domain of CCR5. Also provided are pharmaceutical compositions which comprise the above molecules and methods and uses of same.
Type:
Grant
Filed:
February 18, 2007
Date of Patent:
July 3, 2012
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A prenatal method of analyzing a fetus is disclosed. The method comprising: (a) isolating placental derived microparticles; and (b) analyzing at least one component of the contents of the placental derived microparticles, wherein the at least one component is indicative of a characteristic of the fetus.
Type:
Application
Filed:
June 24, 2010
Publication date:
May 24, 2012
Applicants:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES, FUND FOR MEDICAL RESEARCH DEVELOPMENT OF INFRASTRUCTURE AND HEALTH SERVICES
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Application
Filed:
December 7, 2011
Publication date:
April 26, 2012
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
Type:
Application
Filed:
December 23, 2011
Publication date:
April 19, 2012
Applicants:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.
Type:
Application
Filed:
June 6, 2011
Publication date:
January 5, 2012
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Karl Skorecki, Shay Tzur, Saharon Rosset, Walter Gabriel Wasser, Doron M. Behar, Revital Shemer